ARA-290 (cibinetide)

The foundational mechanistic work was reported by Brines et al. (2004, PNAS), which characterized a heteromeric EPOR/CD131 receptor complex as the structural basis for EPO's tissue-protective signaling, distinct from the erythropoietic EPOR/EPOR homodimer. Brines et al. (2008, PNAS) subsequently delimited tissue-protective activity to short peptide sequences mimicking the helix-B surface of EPO, demonstrating that an 11-amino-acid peptide retains tissue-protective receptor engagement without erythropoietic activity in vitro and in animal models — the molecular basis of ARA-290. Review-level syntheses by Brines and Cerami (2012, Mol Med) describe IRR expression dynamics and the downstream signaling pathways activated by this receptor system; Collino et al. (2015, Pharmacol Ther) provide a broader pharmacological survey of non-erythropoietic EPO-derived peptides studied for tissue-protective properties. Van Velzen et al. (2014, Expert Opinion on Investigational Drugs) contextualize the IRR biology in the setting of translational neuropathy research.

Preclinical neuropathic pain research has examined ARA-290 in rodent model systems. Swartjes et al. (2011, Anesthesiology) studied the compound in a spared-nerve-injury rat model, measuring neuropathic pain behavioral endpoints at extended time points after dosing and comparing outcomes between wild-type and beta-common-receptor (CD131) knockout animals, implicating IRR engagement in the observed model readouts. Swartjes et al. (2014, Molecular Pain) examined dose-dependent allodynia endpoints alongside spinal microglia marker assessments in a related neuropathic pain model. Zhang et al. (2016, Peptides) characterized ARA-290 interaction with TRPV1 channel activity in assays measuring capsaicin-induced mechanical hypersensitivity, proposing an additional direct nociceptor mechanism alongside receptor-mediated anti-inflammatory action.

The sarcoidosis small fiber neuropathy (SFN) program represents the most clinically developed research area for ARA-290. Heij et al. (2012, Mol Med) reported a randomized, double-blind pilot study in sarcoidosis patients with SFN symptoms, measuring the SFN symptom score (SFNSL) over a four-week intravenous administration period. Dahan et al. (2013, Mol Med) reported a Phase 2a randomized, double-blind, placebo-controlled study with endpoints including SFN symptom scores and corneal nerve fiber density assessed by corneal confocal microscopy (CCM); a subsequent erratum (Mol Med, 2016) corrected unit conversions in the corneal nerve fiber density data. Culver et al. (2017, Investigative Ophthalmology & Visual Science) reported the Phase 2b, 28-day, randomized, placebo-controlled trial (NCT02039687), with the primary structural endpoint of corneal nerve fiber area (CNFA) measured by CCM and regenerating intraepidermal GAP-43-positive nerve fibers as surrogate structural endpoints across three study arms.

Brines et al. (2015, Mol Med) reported a Phase 2 study in participants with type 2 diabetes and painful neuropathy, measuring endpoints including HbA1c, lipid profiles, pain questionnaire scores, and corneal nerve fiber density. Preclinical metabolic studies include Muller et al. (2016, Mol Med), which examined ARA-290 in type 2 diabetic Goto-Kakizaki rats with insulin release and glucose tolerance assay readouts, and Collino et al. (2014, Br J Pharmacol), which studied a non-erythropoietic EPO peptide derivative in a diet-induced insulin resistance mouse model using metabolic biomarker endpoints. A registered Phase 2 metabolic study in prediabetes and drug-naive type 2 diabetes (NCT01933529) is listed on ClinicalTrials.gov. Organ-injury research spans renal, cardiac, cutaneous, and shock model contexts: two complementary publications from van Rijt and colleagues (2013, Journal of Translational Medicine) examined ARA-290 in renal ischemia/reperfusion injury models, measuring structural and functional renal endpoints and characterizing post-reperfusion administration timing. Patel et al. (2011, Mol Med) studied a non-erythropoietic peptide mimicking the three-dimensional structure of EPO in an experimental hemorrhagic shock model, measuring organ injury and inflammatory marker endpoints. Bohr et al. (2013, PNAS) examined the helix-B surface peptide in a deep partial-thickness cutaneous burn mouse model, characterizing microvascular and inflammatory marker readouts.

Cardiac model research includes Ueba et al. (2010, PNAS), which examined a non-erythropoietic helix-B peptide in cardiomyocyte and cardiac injury assays measuring TNF-α-induced apoptotic and Akt/ERK/STAT3 pathway endpoints; Ahmet et al. (2013, J Pharmacol Exp Ther), which studied chronic administration of the small non-erythropoietic peptide in a post-myocardial-infarction dilated cardiomyopathy model using structural and functional cardiac endpoints; and Winicki et al. (2023, Frontiers in Cardiovascular Medicine), which examined cardiac inflammatory marker and heart function endpoints in aging animal models. Yao et al. (2021, Cell Transplantation) reported that cibinetide protected isolated human islets under pro-inflammatory conditions in assays relevant to intra-portal islet transplantation research. Nairz et al. (2017, Scientific Reports) characterized cibinetide effects on innate immune cell functional endpoints in an experimental colitis model. Xu et al. (2022, Frontiers in Pharmacology) examined ARA-290 in a chronic-stress depression-like behavior and neuroinflammation mouse model, measuring behavioral and inflammatory marker endpoints. In ophthalmic research, Lois et al. (2020, Journal of Clinical Medicine) reported an open-label Phase 2 pilot study of cibinetide in diabetic macular edema, measuring best-corrected visual acuity, central retinal thickness, central retinal sensitivity, and exploratory metabolic and inflammatory markers. A registered healthy-volunteer study examining ARA-290 effects on cognitive and neural processing of emotional stimuli is listed as completed on ClinicalTrials.gov (NCT02070783).